Ultrasound Features and Clinical Characteristics in Leukemia Patients With Chronic Systemic Candidiasis
| Patient No. . | Diagnosis . | Treatment . | Focal Lesions in the Liver . | Focal Spleen Lesion . | Irregular Pattern During Aplasia . | Autopsy or Biopsy Results (+ = microabscesses) . | CT-liver/ Spleen (+ = focal lesions) . | AP (J/L) GGT (J/L) (max) . | Blood Culture . | CandidaAntibody Titer (max) . | CandidaAntigen Titer (max) . | Outcome (+ = inf. related death) . |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 1 | AML | IVA | + | + | No | ND | + | AP 214 GGT107 | Neg | 1:40,960 | Neg | Alive |
| 2 | AML | DAV | + | No | No | Neg | + | AP 304 GGT170 | Neg | 1:640 | Neg | Alive |
| 3 | CML blast crisis | ViDAP | + | + | No | + | + | AP 416 GGT 69 | Neg | 1:640 | Neg | + |
| 4 | AML | m-amsa/ida | No | No | ++L/−S | + | ND | AP 358 GGT 80 | C tropicalis | 1:640 | Neg | + |
| 5 | AML | DA | + | No | +L and +S (first) | + | ND | AP 738 GGT402 | Neg | 1:40,960 | Neg | + |
| 6 | CML blast crisis | IVA | + | + | No | + | ND | AP 112 GGT 16 | Neg | 1:1,280 | Pos 1:8 | + |
| 7 | ALL | ViDAP | + | + | +L and +S | + | + | AP 960 GGT550 | Neg | 1:20,480 | Neg | Alive |
| 8 | AML | IVA | + | + | No | + | + | AP 311 GGT122 | Neg | 1:2,560 | Neg | Dead, due to AML |
| Patient No. . | Diagnosis . | Treatment . | Focal Lesions in the Liver . | Focal Spleen Lesion . | Irregular Pattern During Aplasia . | Autopsy or Biopsy Results (+ = microabscesses) . | CT-liver/ Spleen (+ = focal lesions) . | AP (J/L) GGT (J/L) (max) . | Blood Culture . | CandidaAntibody Titer (max) . | CandidaAntigen Titer (max) . | Outcome (+ = inf. related death) . |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 1 | AML | IVA | + | + | No | ND | + | AP 214 GGT107 | Neg | 1:40,960 | Neg | Alive |
| 2 | AML | DAV | + | No | No | Neg | + | AP 304 GGT170 | Neg | 1:640 | Neg | Alive |
| 3 | CML blast crisis | ViDAP | + | + | No | + | + | AP 416 GGT 69 | Neg | 1:640 | Neg | + |
| 4 | AML | m-amsa/ida | No | No | ++L/−S | + | ND | AP 358 GGT 80 | C tropicalis | 1:640 | Neg | + |
| 5 | AML | DA | + | No | +L and +S (first) | + | ND | AP 738 GGT402 | Neg | 1:40,960 | Neg | + |
| 6 | CML blast crisis | IVA | + | + | No | + | ND | AP 112 GGT 16 | Neg | 1:1,280 | Pos 1:8 | + |
| 7 | ALL | ViDAP | + | + | +L and +S | + | + | AP 960 GGT550 | Neg | 1:20,480 | Neg | Alive |
| 8 | AML | IVA | + | + | No | + | + | AP 311 GGT122 | Neg | 1:2,560 | Neg | Dead, due to AML |
Abbreviations: DA, daunorubicin/cytosine arabinoside; DAV, daunorubicin, cytosine arabinoside, vepesid; IVA, idarubicin/vepesid/cytosine arabinoside; m-amsa/ida, m-amsacrine/idarubicin; ViDAP, vincristin/daunorubicin/l-asparaginase/prednisone; ND, not done; candida-antibody, indirect haemagglutinin-test (Roche Co, Basel, Switzerland); candida-antigen, CanTec (Ramco-Lab 4507; MT, Mount Vernon, VA); L, liver; S, spleen.